TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12022301
Drug: Trophic feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trophic feeding (0.5‐1 ml h(‐1)) along with parenteral nutrition
Study: 10526805
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.07 +/- 0.03 microgram.kg‐1.min‐1) during desflurane-N2O anesthesia
Study: 8770775
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose interleukin-2 (IL-2) at doses of 1, 3, and 6 x 10(6) IU/day, administered once daily 6 days a week for 12 weeks.
Study: 8770775
Drug: Subcutaneous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subcutaneous low-dose interleukin-2 (IL-2) at doses of 1, 3, and 6 x 10(6) IU/day.
Study: 1827543
Drug: GR32191 (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: GR32191 (120 mg)
Study: 6110040
Drug: Cimetidine therapy
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine therapy (full-dose and maintenance) with food
Study: 22991015
Drug: Conventional PD
Normalized name: Dianeal PD-2/2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional PD solutions (Control)
Study: 21030879
Drug: Lisinopril titrated
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril titrated to 80 mg daily and additional antihypertensives to target SBP < 130 mm Hg
Study: 16943794
Drug: Tadalafil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil (20 mg) on alternate days (ADs) for 4 weeks
Study: 16943794
Drug: Chronic tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic tadalafil administration
Study: 16943794
Drug: On-demand (OD)
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand (OD) tadalafil administration
Study: 16258088
Drug: Intravenous unfractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous unfractionated heparin (continuous infusion of 100 U/kg per day)
Study: 16258088
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution (50 mL/day as a continuous infusion)
Study: 1318081
Drug: 0.20 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.20 mg/kg diazepam
Study: 1318081
Drug: 0.12 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12 mg/kg diazepam
Study: 31741553
Drug: Intrathecal dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal dexamethasone (8 mg) and levobupivacaine (12.5 mg, 0.5%)
Study: 31741553
Drug: Levobupivacaine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (12.5 mg, 0.5%)
Study: 29223101
Drug: Inhalation Anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation Anaesthesia (IA)
Study: 27127650
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow therapy at 37°C
Study: 27127650
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow therapy at 41°C
Study: 27127650
Drug: Nasal high
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal high flow therapy at 37°C and 41°C
Study: 16982936
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (inactivated vaccine, administered intramuscularly)
Study: 16982936
Drug: Influenza vaccination
Normalized name: Haemophilus influenzae b (Ross strain) capsular polysaccharide meningococcal protein conjugate vaccine Injection [PedvaxHIB]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza vaccination (live, attenuated vaccine, administered intranasally)
Study: 14582335
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (SDXP/CQ)
Study: 14582335
Drug: Late treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late treatment failure (asymptomatic)
Study: 31935249
Drug: Body weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight-adjusted dose of palonosetron (1 μg/kg, GI = 40 patients)
Study: 31935249
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of palonosetron (75 μg, GII = 40 patients)
Study: 31935249
Drug: Body weight-adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Body weight-adjusted dose of palonosetron (1 μg/kg, GI)
Study: 31935249
Drug: Fixed dose
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dose of palonosetron (75 μg, GII)
Study: 27398991
Drug: Walking shoes
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Walking shoes with triple‐density, variable‐stiffness midsoles and mild lateral‐wedge insoles worn daily
Study: 20166156
Drug: Fractional CO(2)
Normalized name: CO
DrugBank: Carbon monoxide (DB11588)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional CO(2) laser treatment
Study: 20166156
Drug: Fractional Er:YAG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional Er:YAG laser treatment
Study: 15713002
Drug: Blood orange
Normalized name: ALCOHOL 70 mL in 100 mL TOPICAL SPRAY [All Clean Premium Hand Sanitizer Blood Orange]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood orange juice (600 mL/day)
Study: 12969212
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg/day for 5 days) plus standard care
Study: 8886750
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone 0.25 U/kg/week (subdivided in daily subcutaneous injections, starting with half the dosage for the first four weeks)
Study: 8886750
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone 0.25 U/kg/week
Study: 1352564
Drug: UW preservation
Approvals — FDA: no, EMA: no, PMDA: no
Description: UW preservation solution
Study: 6385759
Drug: Dose 1
Normalized name: Aldose 1-epimerase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 1 of ethyl alcohol resulting in a peak BAC of 100 mg/100 ml
Study: 6385759
Drug: Dose 2
Normalized name: Fluzone High-Dose 2011-2012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose 2 of ethyl alcohol administered when BAC had fallen to one-half the peak BAC from dose 1
Study: 6385759
Drug: Placebo doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo doses administered to five brother-pairs (controls)
Study: 30206728
Drug: Post-infusion scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-infusion scalp cooling for 90 minutes
Study: 30206728
Drug: Post-infusion scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-infusion scalp cooling for 150 minutes
Study: 25128520
Drug: Etanercept (ETN)
Normalized name: Etanercept
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Etanercept (ETN) 50 mg weekly plus Methotrexate (MTX)
Study: 22325110
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg norethindrone (NET)
Study: 22325110
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg norethindrone (NET)
Study: 16278523
Drug: Sustained-release verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release verapamil
Study: 2171852
Drug: Oral amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral amiloride 20 mg
Study: 2171852
Drug: Inhaled amiloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled amiloride 10 ml of 10(‐2) mol/l
Study: 9581
Drug: Chlorpromazine (C)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (C) 10 mg t.i.d. for 7 days, 20 mg t.i.d. for 7 days + Alcohol (A) 0.5 g/kg
Study: 9581
Drug: Thioridazine (T)
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine (T) 10 mg t.i.d. for 7 days, 20 mg t.i.d. for 7 days
Study: 9581
Drug: Sulpiride (S)
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (S) 50 mg t.i.d. + Alcohol (A) 0.5 g/kg
Study: 9581
Drug: Bromazepam (B)
DrugBank: Bromazepam (DB01558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (B) 6 mg t.i.d. + Alcohol (A) 0.5 g/kg
Study: 9581
Drug: Thioridazine (T)
Normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thioridazine (T) + Alcohol (A) 0.5 g/kg
Study: 9581
Drug: Chlorpromazine (C)
Normalized name: Chlorpromazine
DrugBank: Chlorpromazine (DB00477)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorpromazine (C) + Alcohol (A) 0.5 g/kg
Study: 9581
Drug: Sulpiride (S)
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (S) + Alcohol (A) 0.5 g/kg
Study: 9581
Drug: Bromazepam (B)
DrugBank: Bromazepam (DB01558)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromazepam (B) + Alcohol (A) 0.5 g/kg
Study: 18520336
Drug: Probiotics (Lactobacillus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (Lactobacillus GG, S. boulardii, L. reuteri)
Study: 13678108
Drug: DentiPatch (lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DentiPatch (lidocaine patch)
Study: 1597844
Drug: 4g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4g of an oil preparation rich in C18:3n-6, C20:5n-3 and C22:6n-3
Study: 6204153
Drug: Diuretics as
Normalized name: hydralazine hydrochloride / hydrochlorothiazide / reserpine Oral Tablet [Diuretic Ap-Es]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics as sole therapy
Study: 6204153
Drug: Diuretics combined
Normalized name: atenolol and other diuretics, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics combined with alpha-methyldopa or propranolol
Study: 26216382
Drug: Febuxostat (fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat (fixed dose 120 mg)
Study: 26216382
Drug: Allopurinol (low/standard/high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (low/standard/high doses: 200/300/600 mg)
Study: 24352085
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg allopurinol intravenously to the mother immediately prior to delivery
Study: 15661234
Drug: Paclitaxel 175
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 175 mg/m², Carboplatin AUC 5, Gemcitabine 800 mg/m² on day 1 and Gemcitabine 800 mg/m² on day 8, every 3 weeks
Study: 10468948
Drug: Hydrocortisone 15
Normalized name: hydrocortisone 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 15 mg/day
Study: 10468948
Drug: Hydrocortisone 20
Normalized name: hydrocortisone 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 20 mg/day
Study: 10468948
Drug: Hydrocortisone 30
Normalized name: hydrocortisone 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 30 mg/day
Study: 1694831
Drug: Iloprost infusion
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Iloprost infusion (2-4 ng/kg/min for 12 hours daily on 5 consecutive days)
Study: 21098802
Drug: 6-monthly screening
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 6-monthly screening
Study: 21098802
Drug: 12-monthly screening
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 12-monthly screening
Study: 18317624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of midazolam and clonidine (40 microg/kg and 0.5 microg/kg respectively)
Study: 18317624
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of diazepam and clonidine (40 microg/kg and 0.5 microg/kg respectively)
Study: 15774240
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vinorelbine and estramustine phosphate plus ellagic acid (group B)
Study: 15774240
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with vinorelbine and estramustine phosphate (group A)
Study: 9865561
Drug: Cefuroxime (prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefuroxime (prophylactic dose)
Study: 7034642
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanic acid
Study: 2294131
Drug: Evening GH
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening GH injections (2000 h)
Study: 2294131
Drug: Morning GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning GH injections (0800 h)
Study: 368086
Drug: Pirprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pirprofen (600 mg per day)
Study: 368086
Drug: Aspirin (3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (3600 mg per day)
Study: 30052592
Drug: Medication-Assisted Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-Assisted Treatment (MAT)
Study: 20457817
Drug: CXA-101 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-101 (single doses of 250, 500, 1,000, 1,500, and 2,000 mg)
Study: 20457817
Drug: CXA-101 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-101 (multiple doses of 500 mg every 8 h, 1,000 mg every 8 h, and 1,500 mg every 12 h for 10 days)
Study: 20457817
Drug: CXA-101 (1-hour
Approvals — FDA: no, EMA: no, PMDA: no
Description: CXA-101 (1-hour infusion)
Study: 12456849
Drug: Miltefosine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Miltefosine (50 or 100 mg daily for 28 days)
Study: 12456849
Drug: Amphotericin B
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amphotericin B (1 mg per kilogram every other day for a total of 15 injections)
Study: 10350032
Drug: Pemoline (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemoline (3 mg/kg per day, mean dose 2.2 mg/kg per day)
Study: 2401750
Drug: Maxzide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maxzide (25 mg of hydrochlorothiazide and 37.5 mg of triamterene)
Study: 2401750
Drug: Dyazide (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dyazide (25 mg of hydrochlorothiazide and 50 mg of triamterene)
Study: 453712
Drug: Fiberoptic bronchoscopy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fiberoptic bronchoscopy followed by respiratory therapy for 48 hours
Study: 453712
Drug: Respiratory therapy
Normalized name: respiratory therapy supplies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Respiratory therapy alone for 48 hours
Study: 31789006
Drug: Conventional hemostasis
Normalized name: collagen hemostat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional hemostasis (15 mL air injection)
Study: 30910149
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (LDA), 1 capsule/day starting from the 21st day of the cycle prior to gonadotropin stimulation.
Study: 30910149
Drug: Placebo, 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 1 capsule/day starting from the 21st day of the cycle prior to gonadotropin stimulation.
Study: 21334262
Drug: Glycerol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycerol (75 mL four times a day for 4 days)
Study: 21334262
Drug: Placebo (sugar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (sugar solution equivalent volume)
Study: 16886163
Drug: Single-dose lopinavir-ritonavir
Normalized name: lopinavir / ritonavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose lopinavir-ritonavir
Study: 27173369
Drug: Intravenous theophylline
Normalized name: Theophylline
DrugBank: Theophylline (DB00277)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous theophylline (5 mg/kg)
Study: 15237694
Drug: Matched intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched intravenous placebo
Study: 8123409
Drug: Thiopentone 2
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 2 mg kg‐1 + Suxamethonium 1 mg kg‐1
Study: 8123409
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg kg‐1 + Suxamethonium 1 mg kg‐1
Study: 24836213
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for three months
Study: 26685030
Drug: Postoperative adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative adipose derived mesenchymal stem cell treatment
Study: 18266604
Drug: HGS004 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGS004 (40 mg/kg)
Study: 18266604
Drug: HGS004 (8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGS004 (8, 20, and 40 mg/kg)
Study: 18266604
Drug: HGS004 (0.4-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: HGS004 (0.4-40 mg/kg)
Study: 15541412
Drug: ACIDFORM administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACIDFORM administered 0‐30 min precoitus
Study: 15541412
Drug: 2% nonoxynol‐9
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% nonoxynol‐9 (N‐9) product administered 0‐30 min precoitus
Study: 1146927
Drug: Control cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control cycles (no treatment)
Study: 11416735
Drug: Structured Treatment
Normalized name: Lipid,structured (From Sunflower Oil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured Treatment Interruptions (STI)
Study: 9285375
Drug: Intranasal placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (0.9% NaCl) followed by intravenous midazolam (0.05 mg/kg)
Study: 8417420
Drug: Amoxicillin plus
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin plus clavulanate
Study: 8087515
Drug: Combined chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemotherapy and radiotherapy
Study: 30156200
Drug: SRP followed
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP followed by Er, Cr: YSGG laser treatment
Study: 21092500
Drug: Continuous femoral
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous femoral nerve blockade (CFNB) with ropivacaine 0.2% (median infusion rate 5 ml/h)
Study: 21092500
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous analgesia (CIA) with fentanyl 30 µg/kg (2 ml/h)
Study: 9142006
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (40 mg)
Study: 1657084
Drug: Captopril (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (6.25 mg)
Study: 7704492
Drug: Teicoplanin and
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin and aztreonam (antibiotic prophylaxis)
Study: 24743455
Drug: Aqua lymphatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqua lymphatic therapy (ALT) combined with home-based exercise (n = 13)
Study: 21353109
Drug: Prednisone (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (administered orally for 4 weeks before IUI)
Study: 21353109
Drug: Antibody-negative group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody-negative group
Study: 16670077
Drug: recombinant erythropoietin
Normalized name: RECOMBINANT HUMAN ERYTHROPOIETIN ALFA
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant erythropoietin (epoietin) + granulocyte-colony stimulating factor (G-CSF)
Study: 10836911
Drug: Daily subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily subcutaneous ardeparin (100 anti‐Xa IU/kg of body weight)
Study: 8780079
Drug: Zalcitabine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zalcitabine monotherapy (2.25 mg/day)
Study: 8780079
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (2.25 mg/day ddC with zidovudine)
Study: 31182874
Drug: Pregabalin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (1 mg/kg of weight)
Study: 28132867
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg GS-9256 BID
Study: 28132867
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg GS-9256 QD
Study: 28132867
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg GS-9256 BID
Study: 21543993
Drug: Subconjunctival bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subconjunctival bevacizumab (1.25 mg in 0.05 mL)
Study: 21543993
Drug: Bevacizumab soaked
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab soaked in sponges (1.25 mg in 0.05 mL)
Study: 19733018
Drug: Dronabinol (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dronabinol (oral ingestion of therapeutic THC)
Study: 17717037
Drug: Medical management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical management with thrombolytic drugs
Study: 16379317
Drug: TURN treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: TURN treatment
Study: 16379317
Drug: BCG therapy
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG therapy (6 intravesical instillations of Onko BCG)
Study: 9609216
Drug: Nadroparin (20,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (20,500 AXa IU/ml) once daily
Study: 9609216
Drug: Nadroparin (10,250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin (10,250 AXa IU/ml) twice daily
Study: 28170396
Drug: Conventional drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drugs